• Home
  • Kurt Robert Müller
Kurt Robert Müller

Kurt Robert Müller
pharmaLevers GmbH

PhD, MSc, BBA

About

8
Publications
155
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
0
Citations
Introduction
Kurt Robert Müller currently works at pharmaLevers GmbH. Kurt does research in Health Politics and Policy, Public Health and Pharmacy. Their most recent publication is 'ISPOR GLOBAL HEALTH CARE SYSTEM ROAD MAP. Switzerland - Medical Devices and Diagnostics http://www.ispor.org/HTARoadMaps/SwitzerlandMDD.asp'.
Skills and Expertise
Health Technology Assessment
Cost-Effectiveness Analysis
Evidence Based Medicine
Health Care Management
Health Outcomes
Meta-Analysis
Health Management
Chronic Disease Management
Health Care Administration
Decision Analysis
Education
March 2003 - March 2005
GSBA Zurich
Field of study
  • Business Education
March 2003 - March 2005
GSBA Zurich (Graduate School of Business Administration)
Field of study
  • Business Education
November 1979 - December 1988
ETH Zurich
ETH Zurich
Field of study
  • Pharmaceutical Science, Pharmacist

Publications

Publications (8)
Delving into databases to justify high drug prices
Article
  • Apr 1998
Delving into databases to justify high drug prices
Die Versandapotheke - Verkaufsform der Zukunft
Chapter
  • Jan 1998
Gesetzliche Rahmenbedingungen für Managed Care im Pharma-Bereich
Article
  • Jan 1998
Gesetzliche Rahmenbedingungen für Managed Care im Pharma-Bereich.
Managed Care und Medikamente
Article
  • Jan 1998
Pharma Managed Care im Spannungsfeld von Innovation, Qualität und limitierten Ressourcen
Stabilisierung der biologischen Aktivität von Interleukin-2 [Interleukin] durch gemischte Mizellen und Liposomen /
Article
Mikrofiche-Ausg.: 2 Mikrofiches : 24x Zürich, Eidgenössische Techn. Hochsch., Diss., 1989.
Lösungsvorschläge für den Umgang mit kostenintensiven Medikamenten. Sind die angewendeten Preisbildungsmodelle und Managed Entry Agreements (MEAs) für die zwanzig umsatzstärksten Medikamente des Jahres 2019 für das Gesundheitswesen nachhaltig und zielführend? Welche weiteren Optimierungen wären zur Dämpfung der Kostenentwicklung zweckmässig? https://curafutura.ch/uploads/tx_pmxitemlist/pharmaLevers_kostenintensive-Medikamente_Preis-Modelle_100820.pdf
Article
  • Aug 2020
Payer study - Proposed solutions for the handling of cost-intensive medicines. Are the applied pricing models and managed entry agreements (MEAs) for the 20 highest-selling medicines of 2019 sustainable and effective for the healthcare sector? What further optimizations would be appropriate to dampen the cost development? A narrative, solution-ori...
ISPOR GLOBAL HEALTH CARE SYSTEM ROAD MAP. Switzerland - Medical Devices and Diagnostics https://tools.ispor.org/HTARoadMaps/SwitzerlandMDD.asp
Article
  • Jan 2012
https://tools.ispor.org/HTARoadMaps/SwitzerlandMDD.asp
GLOBAL HEALTH SYSTEMS ROAD MAP Switzerland - Pharmaceuticals https://tools.ispor.org/htaroadmaps/SwitzerlandPH.asp
Article
  • Jan 2011
https://tools.ispor.org/htaroadmaps/SwitzerlandPH.asp

Questions

Question (1)
Project - ESMO Magnitude of Clinical Benefit Scale
  • Oct 2018
Question
I understand that ESMO is focusing on clinical benefit assessment. However, taking into account the considerable treatment costs for beneficial cancer drugs an economic statement (or valuation) should be made – at least in a pragmatic way. Of course, this would lead to a lot of controversy but increase the awareness, value and usefulness of the ESMO Value Framework.
Quite possible that I have missed something …
Good luck and best regards,
Kurt

Projects

Project (1)
Lösungsvorschläge für den Umgang mit kostenintensiven Medikamenten
Project